Skip to main content
Premium Trial:

Request an Annual Quote

ABI Reports Increased Revenues for 4th Quarter

Click herefor an updated version of this story.


NEW YORK, July 23 - Applied Biosystems of Applera this morning reported net revenues of $432.9 million for the fourth quarter ending June 30, up over $417 million for the same quarter of 2002, the Foster City, Calif.-based company said in a statement.


The company reported net income of $96.1 million for the quarter, compared to $38.2 million for the year-ago period.


The company recorded research and development charges of $58.2 million, compared to $58.0 million for the same quarter in 2002.


"In light of the challenging business environment, I am pleased that Applied Biosystems achieved solid earnings growth and strong cash flow from operations during the fourth quarter," said Michael Hunkapiller, president, ABI, said in a statement.


The company on Tuesday said that it plans to launch a whole-genome microarray product.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.